Brent was up $1.41, or 3.2%, at $45.02 at 1118 GMT, the first
time it cleared the $45 threshold since early September. U.S.
West Texas Intermediate (WTI) crude also added $1.41 cents, or
3.4%, to $42.77 a barrel.
Both benchmarks had gained nearly 3% on Tuesday.
"This week's news about a coronavirus vaccine was encouraging
and, alongside short-covering activity, strongly supported oil
prices on Monday and Tuesday," said Giovanni Staunovo, oil
analyst for UBS.
The bank cautioned that European lockdowns and restored Libyan
oil output could weigh on prices in the short term, but forecast
oil at $60 a barrel by the end of 2021 based on the likelihood
that producers would continue to rein in supply.
U.S. crude stockpiles fell by 5.1 million barrels last week to
about 482 million barrels, industry group data showed on
Tuesday, compared with analysts' expectations in a Reuters poll
for a reduction of 913,000 barrels. [API/S]
Both Brent and U.S. oil prices are up around 14% this week since
initial trials data showed the experimental COVID-19 vaccine
being developed by Pfizer Inc and Germany's BioNTech was 90%
effective.
Although oil prices are supported by the positive news on the
vaccine, the overall fuel demand outlook remains clouded as
coronavirus restrictions are reimposed in Europe and United
States.
"Hopes of a return to pre-COVID normalcy next year have been
given a huge boost this week. Before then, however, a difficult
winter is on the cards. Infection rates are still accelerating
in several parts of the world including the U.S.," said Stephen
Brennock of broker PVM.
Renewed restrictions in Europe and the United States to combat
the coronavirus have slowed the pace of the fuel demand
recovery, offsetting a rebound in Asian economies where
consumption has almost returned to pre-COVID levels.
(Reporting by Koustav Samanta and Aaron Sheldrick; Editing by
Richard Pullin and Edmund Blair)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|